Abstract: Epithelial ovarian cancer is a cancer of older women. Close to half (45%) of women diagnosed with ovarian cancer will be older than age 64. This ratio is expected to increase in the coming decades as our population ages and life-expectancy improves, while Older women with ovarian cancer receive less surgery and chemotherapy, suffer worse toxicity from surgery and chemotherapy，and have worse survival. The majority of elderly patients are able to tolerate the standard of care for ovarian cancer including initial surgical cytoreduction followed by platinum and taxane chemotherapy. To offer optimal radical management，Pretreatment assessment is needed. Large prospective clinical trials involving elderly ovarian cancer patients are warranted to offer justified evidenced based optimal treatment for those who will be benefited from the treatment.

Key words: Ovarian cancer, Elderly, Surgical cytoreduction, Chemotherapy, Pretreatment assessment